Acadia Pharmaceuticals to Present at Upcoming Investor Conferences
Acadia Pharmaceuticals (Nasdaq: ACAD) will participate in two upcoming investor conferences.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate at the following investor conferences:
10th Annual SVB Leerink Global Healthcare Conference
Fireside Chat Presentation: Friday, February 26, 2021 at 10:40 a.m. Eastern Time
Cowen 41st Annual Health Care Conference
Fireside Chat Presentation: Monday, March 1, 2021 at 12:20 p.m. Eastern Time
These conferences will be held virtually. Live webcasts of the presentations will be accessible on the company’s website, www.acadia-pharm.com, under the investors section and an archived recording will be available on the website for approximately one month following each presentation.
About Acadia Pharmaceuticals
Acadia is trailblazing breakthroughs in neuroscience to elevate life. For more than 25 years we have been working at the forefront of healthcare to bring vital solutions to people who need them most. We developed and commercialized the first and only approved therapy for hallucinations and delusions associated with Parkinson’s disease psychosis. Our late-stage development efforts are focused on dementia-related psychosis, negative symptoms of schizophrenia and Rett syndrome, and in early-stage clinical research we are exploring novel approaches to pain management, and cognition and neuropsychiatric symptoms in central nervous system disorders. For more information, visit us at www.acadia-pharm.com and follow us on LinkedIn.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210218005241/en/